Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/22480336/ below:

Comparative effectiveness of antihypertensive medication for primary prevention of cardiovascular disease: systematic review and multiple treatments meta-analysis

Review

Affiliations

• ¹ Global Health Unit, Norwegian Knowledge Centre for the Health Services, Oslo, Norway. atle.fretheim@nokc.no

• PMID: 22480336
• PMCID: PMC3354999
• DOI: 10.1186/1741-7015-10-33

Item in Clipboard

Review

Atle Fretheim et al. BMC Med. 2012.

• ¹ Global Health Unit, Norwegian Knowledge Centre for the Health Services, Oslo, Norway. atle.fretheim@nokc.no

• PMID: 22480336
• PMCID: PMC3354999
• DOI: 10.1186/1741-7015-10-33

Item in Clipboard

Background: We conducted a systematic review of evidence from randomized controlled trials to answer the following research question: What are the relative effects of different classes of antihypertensive drugs in reducing the incidence of cardiovascular disease outcomes for healthy people at risk of cardiovascular disease?

Methods: We searched MEDLINE, EMBASE, AMED (up to February 2011) and CENTRAL (up to May 2009), and reference lists in recent systematic reviews. Titles and abstracts were assessed for relevance and those potentially fulfilling our inclusion criteria were then assessed in full text. Two reviewers made independent assessments at each step. We selected the following main outcomes: total mortality, myocardial infarction and stroke. We also report on angina, heart failure and incidence of diabetes. We conducted a multiple treatments meta-analysis using random-effects models. We assessed the quality of the evidence using the GRADE-instrument.

Results: We included 25 trials. Overall, the results were mixed, with few significant differences, and with no drug-class standing out as superior across multiple outcomes. The only significant finding for total mortality based on moderate to high quality evidence was that beta-blockers (atenolol) were inferior to angiotensin receptor blockers (ARB) (relative risk (RR) 1.14; 95% credibility interval (CrI) 1.02 to 1.28). Angiotensin converting enzyme (ACE)-inhibitors came out inferior to calcium-channel blockers (CCB) regarding stroke-risk (RR 1.19; 1.03 to 1.38), but superior regarding risk of heart failure (RR 0.82; 0.69 to 0.94), both based on moderate quality evidence. Diuretics reduced the risk of myocardial infarction compared to beta-blockers (RR 0.82; 0.68 to 0.98), and lowered the risk of heart failure compared to CCB (RR 0.73; 0.62 to 0.84), beta-blockers (RR 0.73; 0.54 to 0.96), and alpha-blockers (RR 0.51; 0.40 to 0.64). The risk of diabetes increased with diuretics compared to ACE-inhibitors (RR 1.43; 1.12 to 1.83) and CCB (RR 1.27; 1.05 to 1.57).

Conclusion: Based on the available evidence, there seems to be little or no difference between commonly used blood pressure lowering medications for primary prevention of cardiovascular disease. Beta-blockers (atenolol) and alpha-blockers may not be first-choice drugs as they were the only drug-classes that were not significantly superior to any other, for any outcomes. Review registration: CRD database ("PROSPERO") CRD42011001066.

PubMed Disclaimer

Review flowchart .

Review flowchart .

Review flowchart.

Direct comparisons in network model…

Direct comparisons in network model .

Direct comparisons in network model.

• Beta-blockers for hypertension.

  Wiysonge CS, Bradley HA, Volmink J, Mayosi BM, Opie LH. Wiysonge CS, et al. Cochrane Database Syst Rev. 2017 Jan 20;1(1):CD002003. doi: 10.1002/14651858.CD002003.pub5. Cochrane Database Syst Rev. 2017. PMID: 28107561 Free PMC article. Review.

• Beta-blockers for hypertension. Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, Volmink J. Wiysonge CS, et al. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003. doi: 10.1002/14651858.CD002003.pub2. Cochrane Database Syst Rev. 2007. PMID: 17253471 Updated. Review.
• First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Xue H, Lu Z, Tang WL, Pang LW, Wang GM, Wong GW, Wright JM. Xue H, et al. Cochrane Database Syst Rev. 2015 Jan 11;1:CD008170. doi: 10.1002/14651858.CD008170.pub2. Cochrane Database Syst Rev. 2015. PMID: 25577154 Updated. Review.
• Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.

  Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.

• Comparison of Cardiovascular Events Among Users of Different Classes of Antihypertension Medications: A Systematic Review and Network Meta-analysis.

  Wei J, Galaviz KI, Kowalski AJ, Magee MJ, Haw JS, Narayan KMV, Ali MK. Wei J, et al. JAMA Netw Open. 2020 Feb 5;3(2):e1921618. doi: 10.1001/jamanetworkopen.2019.21618. JAMA Netw Open. 2020. PMID: 32083689 Free PMC article.

• Healthcare costs attributable to abnormal weight in China: evidence based on a longitudinal study.

  Zhao S, Xu X, You H, Ge J, Wu Q. Zhao S, et al. BMC Public Health. 2023 Oct 5;23(1):1927. doi: 10.1186/s12889-023-16855-6. BMC Public Health. 2023. PMID: 37798694 Free PMC article.

• Genetic proxies for calcium channel blockers and cancer: a Mendelian randomization study.

  Fan B, Schooling CM, Zhao JV. Fan B, et al. J Hum Hypertens. 2023 Nov;37(11):1028-1032. doi: 10.1038/s41371-023-00835-9. Epub 2023 Apr 28. J Hum Hypertens. 2023. PMID: 37117874

• The complexity underlying treatment rankings: how to use them and what to look at.

  Chiocchia V, White IR, Salanti G. Chiocchia V, et al. BMJ Evid Based Med. 2023 Jun;28(3):180-182. doi: 10.1136/bmjebm-2021-111904. Epub 2022 May 2. BMJ Evid Based Med. 2023. PMID: 35501121 Free PMC article. No abstract available.

• A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans.

  Xu H, Dorn GW 2nd, Shetty A, Parihar A, Dave T, Robinson SW, Gottlieb SS, Donahue MP, Tomaselli GF, Kraus WE, Mitchell BD, Liggett SB. Xu H, et al. J Pers Med. 2018 Feb 26;8(1):11. doi: 10.3390/jpm8010011. J Pers Med. 2018. PMID: 29495422 Free PMC article.

• The current status of beta blockers' use in the management of hypertension.

  Akbar S, Alorainy MS. Akbar S, et al. Saudi Med J. 2014 Nov;35(11):1307-17. Saudi Med J. 2014. PMID: 25399206 Free PMC article. Review.

1. 1. World Health Organization. The Global Burden Of Disease: 2004 Update. Geneva: WHO; 2008.
2. 1. The World Health Organization. World Health Statistics 2008. Geneva: The World Health Organization; 2008.
3. 1. The World Health Organization. The World Health Report 2002 Reducing Risks, Promoting Healthy Lives. Geneva: The World Health Organization; 2002. - PubMed
4. 1. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827–838. doi: 10.1016/0140-6736(90)90944-Z. - DOI - PubMed
5. 1. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535. - PubMed

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3